Zimmer Partners’s Relay Therapeutics RLAY Stock Holding History

Zimmer Partners’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-16,000	Closed	-$681K	–	159
2020 Q3	$681K	Buy	+16,000	New	+$610K	0.01%	105

Other funds holding RLAY

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Zimmer Partners's RLAY Position: Q4 2020 in Review

Zimmer Partners sold out of Relay Therapeutics (RLAY) in Q4 2020, closing a stake of 16,000 shares — an estimated $681K sold.

Zimmer Partners first reported a position in RLAY in Q3 2020 and held it in 1 quarter. The position peaked at $681K in Q3 2020. 115 funds tracked by Wall St. Rank hold RLAY as of Q4 2020.

Zimmer Partners reported no remaining Relay Therapeutics position as of Q4 2020 after selling out during the quarter.
Zimmer Partners sold 16,000 Relay Therapeutics shares in Q4 2020, an estimated $681K.
Zimmer Partners first reported a position in Relay Therapeutics in Q3 2020 and held it in 1 quarter.
Zimmer Partners's Relay Therapeutics position peaked at $681K in Q3 2020.
115 funds tracked by Wall St. Rank held Relay Therapeutics as of Q4 2020.

Based on Zimmer Partners's 13F filing for Q4 2020, filed 16 Feb 2021.